Menopause

Condition: Menopause  |  Category: Hormonal Health  |  Reviewed by: Brian Lamkin, DO

What Is Menopause?

Menopause is the permanent cessation of menstruation following 12 consecutive months without a menstrual period, occurring as a result of the decline of ovarian follicle reserve and the consequent loss of estradiol and progesterone production. The average age of natural menopause in the United States is 51 years, with a normal range from 45 to 56. Surgical menopause, produced by bilateral oophorectomy, results in an abrupt and often more severe hormonal transition than natural menopause.

The term menopause is technically the single day marking 12 months of amenorrhea, but clinically it describes the postmenopausal state in which ovarian estradiol and progesterone production have substantially ceased and the hormonal environment has stabilized at a new, lower set point. This postmenopausal hormonal environment has profound and sustained consequences for cardiovascular health, bone density, cognitive function, metabolic health, sleep quality, and quality of life.

Effective menopause management requires understanding that the hormonal deficits of menopause are not merely symptomatic but represent the withdrawal of hormones that were cardioprotective, neuroprotective, and bone-protective. The timing of intervention relative to the transition significantly affects both the symptom burden and the long-term health consequences.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

While the ovarian estradiol and progesterone decline is the primary driver of menopause, the severity of symptoms and long-term health consequences are modulated by multiple addressable factors that determine how the body adapts to the hormonal transition.

Estradiol Deficiency and Receptor Sensitivity

The vasomotor symptoms, cognitive changes, bone loss, and cardiovascular risk acceleration of menopause are primarily driven by estradiol withdrawal from tissues that have estrogen receptors including blood vessels, bone, brain, and the urogenital epithelium. The severity of these consequences is modulated by receptor sensitivity, the degree of residual adrenal estrogen production through DHEA-to-estrone conversion, and the timing and adequacy of hormone replacement when initiated.

HPA Axis Dysregulation and Cortisol Amplification

HPA axis dysfunction is extraordinarily common in menopausal women and dramatically amplifies the vasomotor symptom burden. Cortisol drives the thermoregulatory instability that underlies hot flashes independently of estradiol through hypothalamic CRH receptor signaling. Women entering menopause with pre-existing HPA dysregulation experience vasomotor symptoms that respond poorly to estrogen therapy alone and require concurrent cortisol management for adequate relief.

Thyroid Dysfunction and Metabolic Acceleration

Thyroid dysfunction, particularly Hashimoto's thyroiditis, is more prevalent in menopausal women and produces overlapping symptoms including fatigue, brain fog, weight gain, and mood changes. The loss of estradiol's insulin-sensitizing effects at menopause accelerates insulin resistance and visceral fat accumulation, compounds the metabolic burden, and requires dietary and lifestyle intervention alongside hormone therapy for adequate management.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

A complete menopause evaluation requires characterizing all relevant hormonal axes alongside the metabolic and inflammatory consequences of estradiol withdrawal.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The undertreated vasomotor symptom patient on standard therapy: on oral conjugated equine estrogens with persistent breakthrough hot flashes and night sweats; switching to transdermal bioidentical estradiol at an individualized dose with micronized progesterone resolves vasomotor symptoms that oral synthetic therapy could not control; the route and molecular form both matter
• The menopausal woman with compound HPA and hormonal dysfunction: estradiol deficiency and cortisol dysregulation combined; estrogen therapy provides incomplete vasomotor control; adding cortisol-targeted support through adaptogenic intervention and sleep optimization dramatically reduces residual hot flash frequency and severity
• The postmenopausal woman with accelerating metabolic dysfunction: progressive visceral fat accumulation, rising fasting insulin, deteriorating lipid profile, and new onset of hypertension beginning 2 to 3 years after menopause; estradiol replacement addresses the insulin-sensitizing deficit while targeted metabolic intervention through dietary modification and resistance training addresses the compositional consequences
• The surgical menopause patient with abrupt onset and severe symptoms: bilateral oophorectomy at age 45 producing immediate severe vasomotor symptoms, sleep disruption, mood instability, and cognitive changes; the abruptness and severity require prompt, comprehensive hormonal replacement rather than the gradual titration appropriate for natural menopause

Treatment and Optimization Strategy

Bioidentical Hormone Therapy Individualized to Measured Deficiencies

Transdermal bioidentical estradiol provides the most physiologically appropriate estrogen replacement, bypassing first-pass hepatic metabolism and avoiding the SHBG elevation, coagulation factor activation, and VTE risk associated with oral estrogen. Micronized progesterone provides uterine protection with an improved side-effect profile compared to synthetic progestins and provides sleep-promoting and anxiolytic effects through GABA receptor modulation. Low-dose testosterone addresses the androgen component of menopausal fatigue, libido, and cognitive symptoms.

What Most Doctors Miss

• The route of estrogen delivery matters significantly: oral estrogen undergoes first-pass hepatic metabolism, elevates SHBG and C-reactive protein, and carries higher VTE risk than transdermal delivery; transdermal estradiol at equivalent biological doses does not carry the same thrombotic risk and is the appropriate first-line delivery route for most menopausal women; this distinction is not communicated in most standard menopause management conversations
• Testosterone deficiency is not addressed in standard menopause management: testosterone declines with age and adrenal reserve through both the perimenopausal and postmenopausal period; its deficiency contributes substantially to the fatigue, libido loss, cognitive symptoms, and reduced lean mass of menopause that estradiol and progesterone alone do not resolve; testosterone is the most under-prescribed hormone in menopausal women
• The HPA component of vasomotor symptoms is not evaluated: cortisol drives thermoregulatory instability through hypothalamic mechanisms independent of estradiol; women with severe, refractory hot flashes often have a cortisol component that accounts for the inadequate response to standard estrogen therapy; without a diurnal cortisol assessment this mechanism is never identified
• The timing hypothesis is not communicated: hormone therapy initiated within 10 years of menopause onset provides cardiovascular and cognitive protective benefits that therapy initiated later does not; many women are told to wait until symptoms are severe before initiating therapy, sacrificing the window during which the most meaningful long-term protection is achievable

When to Seek Medical Care

Women entering or having completed the menopausal transition who are experiencing symptoms impairing quality of life should seek evaluation for individualized hormone therapy rather than accepting symptom severity as inevitable. The early postmenopausal years represent the window of maximum benefit from hormone therapy for both symptom relief and long-term health protection.

Seek prompt evaluation for new onset of significant chest pain, severe headaches, or unilateral leg swelling on hormone therapy, as these warrant urgent evaluation to exclude venous thromboembolic or cardiovascular events. Women with a history of hormone-sensitive cancers require individualized oncological guidance before hormone therapy is initiated.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Menopause

At The Lamkin Clinic, menopause evaluation begins with a comprehensive panel that includes estradiol, progesterone, free testosterone, SHBG, DHEA-S, FSH, LH, DUTCH complete hormone metabolites, four-point cortisol, full thyroid axis, and fasting insulin. We treat the entire hormonal picture rather than the presenting vasomotor symptom alone. Hormone therapy is individualized, monitored with repeat testing every 3 to 6 months, and adjusted based on measured response and symptom resolution.

Related Conditions

Related Symptoms